Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction

RCT (n=5050) found a lower risk of death from cardiovascular causes or hospitalisation for heart failure with vericiguat vs placebo at median 10.8 months (35.5% vs 38.5%, HR 0.90, 95% CI 0.82-0.98).

SPS commentary:

A review published in a separate journal (Circulation) summarises this study investigating vericiguat for heart failure and compares the results with the PARADIGM-HF (sacubitril/valsartan), and DAPA-HF (dapagliflozin) studies, highlighting that comparison of agents is difficult as studies had different eligibility criteria.


New England Journal of Medicine

Resource links:

Review in Circulation Journal